Table 1 Association of EpCAM expression and patient clinicopathological characteristics in NPC tissues
Characteristics | No. | EpCAM expression level | P-value (χ2-test) | |
|---|---|---|---|---|
| Â | Â | Low | High | Â |
Gender | ||||
  Male | 47 | 24 (51.1%) | 23 (48.9%) | 0.164 |
  Female | 17 | 12 (70.6%) | 5 (29.4%) |  |
Age | ||||
  <44 | 32 | 17 (53.1%) | 15 (46.9%) | 0.200 |
  ≥44 | 32 | 22 (68.8%) | 10 (31.2%) |  |
DNA copy | ||||
  ≤4000 | 40 | 22 (55.0%) | 18 (45.0%) | 0.795 |
  >4000 | 24 | 14 (58.3%) | 10 (41.7%) |  |
EA/IgA | ||||
  <1:10 | 14 | 8 (57.1%) | 6 (42.9%) | 0.939 |
  ≥1:10 | 50 | 28 (56.0%) | 22 (44.0%) |  |
VCA/IgA | ||||
  <1:80 | 10 | 4 (40.0%) | 6 (60.0%) | 0.259 |
  ≥1:80 | 54 | 32 (59.3%) | 22 (40.7%) |  |
T-stage | ||||
  T1–2 | 20 | 11 (55.0%) | 9 (45.0%) | 0.892 |
  T3–4 | 44 | 25 (56.8%) | 19 (43.2%) |  |
N-stage | ||||
  N0–1 | 31 | 19 (61.3%) | 12 (38.7%) | 0.431 |
  N2–3 | 33 | 17 (51.5%) | 16 (48.5%) |  |
Clinical staging | ||||
  I–II | 4 | 3 (75.0%) | 1 (25.0%) | 0.435 |
  III–IV | 60 | 33 (55.0%) | 27 (45.0%) |  |
Distant metastasis | ||||
  Yes | 15 | 3 (28.6%) | 12 (80.0%) | 0.001* |
  No | 49 | 33 (67.3%) | 16 (32.7%) |  |
